London-based Purespring raised €95M in a Series B funding round led by Sofinnova Partners to initiate a Phase I/II clinical trial for IgAN.
London-based Purespring raised €95M in a Series B funding round led by Sofinnova Partners to initiate a Phase I/II clinical trial for IgAN.
10/12/24, 6:09 AM
Location
londonMoney raised
€95 million
Industry
biotechnology
Investors
Syncona Limited, British Patient Capital, Gilde Healthcare, Forbion, Sofinnova Partners
Purespring has secured £80M (approx €95M) in an oversubscribed Series B funding round. The funding will support its pipeline, including initiating a clinical trial for a chronic kidney disease.
Company Info
Location
london, england, united kingdom
Additional Info
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.